Edwards Lifesciences stock popped Wednesday on strong sales of its TAVR procedures, leading to a top- and bottom-line beat.

Over the last two decades, Edwards Lifesciences has demonstrated that it knows how to maintain leadership through innovation of tissue heart valves. Edwards remains the dominant force in surgical ...

Edwards Lifesciences Corp. engages in the ... Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter Heart ...

Feb 11 (Reuters) - Edwards Lifesciences (EW.N), opens new tab beat analysts' estimate for fourth-quarter profit on Tuesday, helped by strong demand for its artificial heart valves and other ...

Edwards Lifesciences (NYSE:EW) reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This ...

Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this ...

The tricuspid valve is anatomically complex. It’s often called the “forgotten valve” because of its position in the back of ...

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024.